Introduction
============

Latent autoimmune diabetes in adults (LADA) is a slowly progressive form of autoimmune diabetes that presents an initial type 2 diabetes mellitus (T2DM) phenotype combined with diabetes-related autoantibodies ([@ref-23]). At diagnosis, patients do not require insulin therapy and are often classified as T2DM patients ([@ref-16]; [@ref-32]). Patients with LADA are younger and leaner that T2DM patients ([@ref-16]; [@ref-32]). They usually have a lower body mass index (BMI), serum triglycerides (TG), waist circumference (WC), waist-to-hip ratio, and blood pressure (BP) and higher HDL cholesterol levels than the T2DM population ([@ref-14]; [@ref-17]; [@ref-16]; [@ref-21]; [@ref-25]). The cardiovascular risk profile of LADA is intermediate, falling between that of type 1 and type 2 diabetes. Additionally, these patients show lower residual endogenous insulin secretion and progress more rapidly to insulin treatment with worse glycemic control ([@ref-14]; [@ref-17]; [@ref-21]; [@ref-25]; [@ref-18]).

Quality of life (QoL) is a subjective measure of health and well-being related to disease. It includes psychosocial features, physical functioning, mobility and personal care ([@ref-13]). The aim of measuring QoL is to provide a more comprehensive, integral, precise and valid evaluation of patients' health status ([@ref-31]). Treatment satisfaction (TS) is an individual subjective measure that assesses the patients' experience of treatment processes and results, including ease of use, side effects and efficacy ([@ref-19]). TS can be influenced by demographic characteristics such as age, educational level and salary ([@ref-34]). The development of the disease, information regarding treatment, therapy availability and costs are also associated with TS ([@ref-34]). Furthermore, diabetes mellitus reportedly has a negative impact QoL, but TS is optimal in this population ([@ref-31]).

Previous studies have investigated the QoL and TS of patients with type 1 diabetes mellitus (T1DM) and T2DM, but not those with LADA ([@ref-1]; [@ref-7]; [@ref-12]; [@ref-26]; [@ref-27]). The PANORAMA study found that T2DM patients with poor glycemic control, complex treatments and severe hypoglycemic episodes showed poorer QoL compared with patients without these factors ([@ref-7]; [@ref-12]). Other studies observed that QoL and treatment satisfaction were lower with increasing age, female sex, lower education level, insulin treatment and obesity, the presence of diabetic comorbidities, poorer glycemic control and lower socioeconomic status ([@ref-1]; [@ref-26]; [@ref-27]).

As the diagnosis of LADA among subjects with type 2 diabetes is usually delayed, which may increase the disease burden, we hypothesized that LADA patients might have a lower QoL and TS than their counterparts with T2DM; however, LADA is an autoimmune form of diabetes that usually evolves into a phenotype closely related to that of classical type 1 diabetes. Furthermore, the identification of LADA subjects may be relevant from the clinical point of view.

To our knowledge, no studies have evaluated QoL and TS in subjects with LADA. Therefore, the primary objective of this study was to assess QoL and TS in patients with LADA and to compare these measures with those of T2DM and T1DM patients. We also evaluated the factors related to both QoL and TS in the study subjects.

Materials and Methods
=====================

The study design was observational and cross-sectional. LADA was defined as diabetes diagnosed in individuals over 30 years of age with a positive test for glutamic acid decarboxylase (GAD) antibodies and without the need for insulin treatment during the first six months after diagnosis ([@ref-22]; [@ref-25]). Patients with T1DM and T2DM were diagnosed according to the current standard diagnostic criteria, as described previously ([@ref-25]). The inclusion criteria for the three groups of patients were as follows: a diagnosis of diabetes mellitus with a disease duration of more than one year; age greater than 18 years; absence of disability due to macrovascular complications (including a history of diabetic foot disease); and absence of macroalbuminuria (defined as urine albumin-to-creatinine ratio \>300 mg/g) or renal failure (estimated glomerular filtration rate \<60 ml/min/1.73 m^2^). The exclusion criteria were as follows: conditions that could affect the results, such as dementia, mental diseases, hearing and languages problems, pregnancy and disability due to cardiovascular diseases. Dementia and mental diseases had to be diagnosed by a physician and could be determined using the registered clinical records of the patient's general practitioner. No screening tools for detecting initial cognitive impairment were used. All included patients had an estimated glomerular filtration rate \>60 ml/min, except for two LADA participants who had a glomerular filtration rate between 30 and 59 ml/min. Two patients in the T1DM group had previous cerebrovascular events, and one patient had bilateral femoral stenosis; none of the patients had any disability. The study was approved by the Ethics Committee of Hospital Arnau de Vilanova (Ethical Application Ref: CEIC 1079 and Ref: PI-13-095). Written informed consent was obtained from all of the subjects.

Clinical variables
------------------

Trained researchers (MG-C and NA) conducted personal interviews with each of the patients and reviewed the medical records to collect the data regarding the variables of interest. Anthropometric measures were determined according to standard criteria. Laboratory tests and blood pressure were measured using standard procedures as previously described ([@ref-2]). Hypertension and dyslipidemia were defined if the participant was undergoing pharmacological treatment for these conditions. Microalbuminuria was defined as an albumin creatinine ratio \>30 mg/g. Physical activity was assessed using a validated method by [@ref-4]; participants were classified as engaging in regular exercise if they performed any physical activity that required at least ≥4 METS (The Metabolic Equivalent) of brisk walking for 30 min or more and as sedentary if they did not perform any daily physical activity or if they engaged less than 30 min of physical activity per day ([@ref-4]; [@ref-10]).

Quality of life
---------------

QoL was assessed through the Audit of Diabetes-Dependent Quality of Life (ADDQoL-19), a disease-specific QoL questionnaire designed and validated in diabetic Spanish subjects ([@ref-7]; [@ref-9]; [@ref-12]) ([File S1](#supp-1){ref-type="supplementary-material"}). This questionnaire consists of 21 items, of which 19 are related to specific life domains and are scored on a 5-point scale. The impact of diabetes on each domain is weighted according to the importance of the domain to the patient's QoL and is reported as the average weighted impact score. These scores can range from +9 (maximum positive impact) to −3 (maximum negative impact). The first two items are general and are scored separately. The first item measures current QoL and is scored from +3 (excellent) to −3 (very bad). The second item measures diabetes-specific QoL and ranges from −3 (maximum negative impact) to +1 (maximum positive impact). Moreover, five of the 19 items that may not have importance for some patients are included in a preliminary question that can be ignored if not applicable. All the questionnaires were administered individually by two trained interviewers (MG-C and NA.).

Treatment satisfaction
----------------------

TS was determined by a diabetes-specific questionnaire, the Diabetes Treatment Satisfaction Questionnaire status-version (DTSQ-s) ([@ref-6]), that has been validated for the Spanish diabetic population ([@ref-15]) ([File S2](#supp-2){ref-type="supplementary-material"}). This questionnaire consists of eight items scored on a 6-point scale. The final score is weighted according to six items with total scores ranging from 36 (very satisfied) to 0 (very unsatisfied). The two remaining items measure the frequency of hyperglycemia and hypoglycemia, respectively, and are scored on a scale from 0 (never) to 6 (always).

Sample size
-----------

To our knowledge, no previous studies have reported QoL and TS in patients with LADA. Additionally, the number of subjects with LADA is limited at the local level, and we aimed to recruit all available patients.

Statistical analysis
--------------------

The statistical analysis included the comparability among the groups of subjects with diabetes (LADA, T2DM and T1DM) and multivariate linear regression models' estimation of the variability of the overall mean score for QoL and the present QoL and diabetes-specific QoL items provided by the ADDQoL questionnaire. The TS score and the hyperglycemia and hypoglycemia frequencies were also fitted in multivariate linear regression models to identify differences between the types of diabetes after adjustment for significantly related patient characteristics. The comparison of QoL and TS between the diabetic groups was stratified by the median of the two groups. In the multivariate linear regression models, LADA patients undergoing insulin treatment were used as the reference group in all of the analyses. The comparability analysis included Pearson's chi-squared test (or Fisher's exact test in the case of any expected frequency lower than 5) to compare the distribution of qualitative characteristics. The Kruskal-Wallis test was performed to compare the distribution of quantitative characteristics, including pairwise comparisons to adjust for multiple testing according to the Benjamini & Hochberg method; furthermore, these characteristics were described by median and interquartile intervals for each diabetic group. The significance level was set at 0.05. The statistical software R version 3.3.2 ([@ref-28]) was used for the analyses.

Results
=======

We had previously identified a total of 106 LADA patients in the local cohort of the only reference hospital in Lleida (North-Eastern Spain). This hospital is the public reference center for specialized diabetes care for the health care district of Lleida. From this sample, 20 participants were excluded after the initial screening based on the exclusion criteria. From a sample of 86 LADA patients who were contacted to participate in the study, 51 participants initially accepted, and an additional three patients were excluded. Thus, 48 LADA patients were included in the study. From a sample of 170 T1DM patients who were contacted to participate in the study, a total of 127 agreed to participate, and 3 were excluded for pregnancy, yielding a final sample of 124 patients. As a comparison with T2DM, we used the entire group of 297 patients with T2DM who had been included in a previous study of QoL conducted at the same center ([@ref-2]).

The comparison between the patients with LADA included in the study and those who refused to participate (*n* = 35) revealed no differences in clinical characteristics except for a lower frequency of insulin treatment in the non-participant group (72%; *p* = 0.049 for the comparison with the LADA patients included in the current study).

The clinical and demographic characteristics of the study groups are shown in [Table 1](#table-1){ref-type="table"}. The LADA patients had an intermediate cardiovascular risk profile in terms of adiposity, lipids and blood pressure compared with the T2DM and T1DM groups. The patients with LADA were older than those with T1DM (*p* \< 0.001). The duration of diabetes in the LADA group was longer (10.7 years) than that of the T2DM group (8 years) and shorter than that of the T1DM group (20.5 years; *p* \< 0.001). The frequency of diabetic retinopathy (DR) was 22.9% in the LADA group, 49.8% in the T2DM group and 40.3% in the T1DM group (*p* = 0.001). There were no differences in glycated hemoglobin (HbA1c) among the 3 groups (*p* = 0.689).
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###### Clinical characteristics of the study groups.

![](peerj-05-3928-g001)

  Characteristics                   LADA (*N* = 48)       T2DM (*N* = 297)      T1DM (*N* = 124)      *p*-value[^\*^](#table-1fn1){ref-type="fn"}   *p*-LADA vs. T2DM   *p*-LADA vs. T1DM
  --------------------------------- --------------------- --------------------- --------------------- --------------------------------------------- ------------------- -------------------
  Age (years)                       62 \[53.8;70.2\]      60 \[52.0;68.0\]      46 \[37.0;53.0\]      \<0.001                                       0.118               \<0.001
  Sex, male                         26 (54.2)             151 (50.8)            57 (46.0)             0.543                                                             
  Education level                                                                                     \<0.001                                       0.181               0.012
  \<Primary                         3 (6.3)               38 (12.8)             17 (13.7)                                                                               
  Primary                           24 (50.0)             169 (56.9)            31 (25.0)                                                                               
  Secondary                         18 (37.5)             69 (23.2)             54 (43.5)                                                                               
  Graduate or higher                3 (6.3)               21 (7.1)              22 (17.7)                                                                               
  Smoking                                                                                             0.891                                                             
  Non-smoker                        24 (50.0)             139 (47.3)            57 (46.0)                                                                               
  Smoker, current                   11 (22.9)             62 (21.1)             31 (25.0)                                                                               
  Smoker, former                    13 (27.1)             93 (31.6)             36 (29.0)                                                                               
  Physical activity                                                                                   0.052                                                             
  Sedentary                         13 (27.1)             114 (38.4)            34 (27.4)                                                                               
  Regular physical activity         35 (72.9)             183 (61.6)            90 (72.6)                                                                               
  Diabetes duration (years)         10.7 \[6.5;16.7\]     8 \[4.0;15.0\]        20.5 \[14.0;30.2\]    \<0.001                                       0.035               \<0.001
  BMI (kg/m^2^)                     27.1 \[24.1;30.4\]    30.6 \[28.1;34.7\]    24.6 \[22.5;27.2\]    \<0.001                                       \<0.001             0.001
  Waist (centimeters)               96.7 ± 15.5           106 ± 11.8            87.7 ± 12.8           \<0.001                                       \<0.001             \<0.001
  Hypertension                      26 (54.2)             168 (56.6)            41 (33.1)             \<0.001                                       0.878               0.027
  Systolic blood pressure (mmHg)    134 \[124.0;148.0\]   139 \[127.0;150.0\]   127 \[113.0;139.0\]   \<0.001                                       0.220               0.017
  Diastolic blood pressure (mmHg)   73 \[69.0;79.0\]      77 \[70.0;84.0\]      73 \[65.0;78.2\]      \<0.001                                       0.126               0.235
  Dyslipidemia                      34 (70.8)             131 (44.1)            55 (44.4)             0.002                                         0.003               0.005
  Diabetic retinopathy              11 (22.9)             148 (49.8)            50 (40.3)             0.001                                         0.003               0.075
  Microalbuminuria                  11 (23.4)             43 (14.5)             11 (9.1)              0.051                                                             
  Insulin treatment                 43 (89.6)             97 (32.7)             124 (100.0)           \<0.001                                       \<0.001             0.001
  HbA1c (%)                         7.5 \[6.9;8.2\]       7.6 \[6.8;8.5\]       7.6 \[7.0;8.1\]       0.689                                                             
  Total cholesterol (mg/dL)         176 \[155.0;202.0\]   181 \[163.0;205.0\]   182 \[165.0;202.0\]   0.553                                                             
  HDL-c (mg/dL)                     58.5 \[40.8;70.2\]    48 \[41.8;59.0\]      63 \[53.9;74.0\]      \<0.001                                       0.040               0.011
  LDL-c (mg/dL)                     101 \[84.0;123.0\]    106 \[87.2;128.0\]    102 \[89.6;116.0\]    0.391                                                             
  Triglycerides (mg/dL)             91.5 \[66.8;134.0\]   117 \[83.0;167.0\]    65.5 \[53.8;81.2\]    \<0.001                                       0.003               \<0.001

**Notes.**

*p*-value for comparison between groups.

LADAlatent autoimmune diabetes of adultT2DMtype 2 diabetes mellitusT1DMtype 1 diabetes mellitusBMIbody mass indexHbA1cglycated haemoglobinHDL-chigh-density lipoprotein cholesterolLDL-clow-density lipoprotein cholesterol

Data are median \[interquartile\], *n* (%) or means ± SD.

Quality of life
---------------

The scores for current QoL did not differ among the 3 study groups (*p* = 0.503; [Table 2](#table-2){ref-type="table"}); however, there was a higher proportion of patients with negative diabetes-specific QoL in the LADA group (70.8%) than in the T2DM group (52.9%; *p* = 0.045). Furthermore, more subjects with LADA had a negative average weighted impact score (60.4%) compared with the T2DM patients (37.7%; *p* = 0.007). Concerning these QoL measures, we could not find differences between the LADA and T1DM patients.
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###### Descriptive analysis for the Audit of Diabetes Dependent Quality of Life (ADDQoL) results of the study groups.

![](peerj-05-3928-g002)

  Items                           LADA (*N* = 48) *n* (%)   T2DM (*N* = 297) *n* (%)   T1DM (*N* = 124) *n* (%)   *p*-value[^\*^](#table-2fn2){ref-type="fn"}   *p*-LADA vs. T2DM   *p*-LADA vs. T1DM
  ------------------------------- ------------------------- -------------------------- -------------------------- --------------------------------------------- ------------------- -------------------
  Present QoL                                                                                                     0.503                                                             
  \[−3,2)                         42 (87.5)                 242 (81.5)                 99 (79.8)                                                                                    
  \[2,3\]                         6 (12.5)                  55 (18.5)                  25 (20.2)                                                                                    
  Diabetes-specific QoL                                                                                           \<0.001                                       0.045               0.634
  \[−3,0)                         34 (70.8)                 157 (52.9)                 94 (75.8)                                                                                    
  \[0,2\]                         14 (29.2)                 140 (47.1)                 30 (24.2)                                                                                    
  Average weighted impact score                                                                                   \<0.001                                       0.007               0.069
  \[−6.526,−0.842)                29 (60.4)                 112 (37.7)                 94 (75.8)                                                                                    
  \[−0.842,0.316\]                19 (39.6)                 185 (62.3)                 30 (24.2)                                                                                    

**Notes.**

The groups are stratified by medians.

*p*-value for comparison between groups.

QoLquality of lifeLADAlatent autoimmune diabetes of adultT2DMtype 2 diabetes mellitusT1DMtype 1 diabetes mellitus

The multivariate linear model of the diabetes-specific QoL score revealed a significant interaction with insulin treatment, as indicated in [Table 3](#table-3){ref-type="table"}. The results are expressed using the group of insulin-treated patients with LADA as the reference group. The LADA and T2DM subjects without insulin treatment showed a higher diabetes-specific QoL than the reference group (*p* = 0.004 and *p* \< 0.001, respectively), whereas there were no differences between the patients with T1DM and insulin-treated T2DM patients. Additionally, the presence of hypertension, longer disease duration and a larger waist circumference had a negative impact on diabetes-specific QoL.
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###### Multivariate linear regression for the Audit of Diabetes Dependent Quality of Life (ADDQoL) diabetes-specific QoL score.

![](peerj-05-3928-g003)

  Coefficients                                             Estimate    Standard error   *p* value
  -------------------------------------------------------- ----------- ---------------- -----------
  Intercept                                                0.278998    0.407968         0.490
  T2DM[^\*^](#table-3fn3){ref-type="fn"} without insulin   0.815249    0.154823         \<0.001
  LADA[^\*^](#table-3fn3){ref-type="fn"} without insulin   1.187429    0.415424         0.004
  T2DM[^\*^](#table-3fn3){ref-type="fn"} insulin           0.238438    0.168811         0.160
  T1DM                                                     0.024457    0.164031         0.880
  Hypertension                                             −0.310550   0.089091         0.001
  HbA1c                                                    −0.070135   0.035407         0.050
  Disease duration                                         −0.010606   0.004989         0.030
  Waist circumference                                      −0.008147   0.003458         0.020

**Notes.**

Multiple R-squared: 0.2284 (27 cases with missing information for any variable in the model).

Reference group: LADA patients receiving insulin treatment.

Indicates the existence of interactions between variables.

LADAlatent autoimmune diabetes of adultT2DMtype 2 diabetes mellitusT1DMtype 1 diabetes mellitusHbA1cglycated haemoglobin

Concerning the ADDQoL average weighted impact score, we found a significant interaction between DR, the study group (i.e., type of diabetes) and insulin treatment ([Table 4](#table-4){ref-type="table"}). Insulin-treated LADA subjects showed a poorer average weighted impact score than their corresponding type 2 non-insulin-treated counterparts (*p* \< 0.001). Additionally, T2DM patients with DR and with (*p* = 0.01) or without (*p* = 0.03) concomitant insulin treatment and T1DM patients with DR (*p* = 0.03) had a better average weighted impact score than LADA patients undergoing insulin treatment. The presence of DR, longer disease duration, lower education level (less than a primary education) and former smoking had a negative impact on the average weighted impact score. Nevertheless, physical activity was positively related to this measure of QoL (*p* = 0.010). Furthermore, using the LADA patients undergoing insulin treatment with or without DR as reference groups, we could estimate the combined coefficients using the same model ([Table S1](#supp-3){ref-type="supplementary-material"}). These analyses showed that LADA subjects with DR who were treated with insulin showed a lower QoL than any other combination of diabetes type, insulin treatment and DR. Furthermore, the LADA patients undergoing insulin treatment without DR had a lower QoL than the T2DM patients without insulin treatment either with (*p* = 0.006) or without DR (*p* \< 0.001).
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###### Multivariate linear regression for the Audit of Diabetes Dependent Quality of Life (ADDQoL) average weighted impact score.

![](peerj-05-3928-g004)

  Coefficients                                                                                  Estimate   Standard error   *p* value
  --------------------------------------------------------------------------------------------- ---------- ---------------- -----------
  Intercept                                                                                     −1.29375   0.21782          \<0.001
  T2DM[^\*^](#table-4fn3){ref-type="fn"} without insulin                                        0.95200    0.20699          \<0.001
  LADA[^\*^](#table-4fn3){ref-type="fn"} without insulin                                        1.06176    0.64037          0.100
  T2DM[^\*^](#table-4fn3){ref-type="fn"} insulin                                                0.10006    0.31884          0.750
  T1DM                                                                                          −0.04103   0.22328          0.850
  DR                                                                                            −1.25952   0.40942          0.002
  Disease duration                                                                              −0.01674   0.00663          0.010
  No education[^\*\*^](#table-4fn4){ref-type="fn"}                                              −0.45008   0.15383          0.004
  Physical activity                                                                             0.27361    0.10539          0.010
  Smoker, current                                                                               −0.21031   0.12937          0.100
  Smoker, former                                                                                −0.30882   0.11674          0.008
  T2DM[^\*^](#table-4fn3){ref-type="fn"} without insulin[^\*^](#table-4fn3){ref-type="fn"} DR   0.92912    0.43927          0.030
  LADA[^\*^](#table-4fn3){ref-type="fn"} without insulin[^\*^](#table-4fn3){ref-type="fn"} DR   1.10620    1.05301          0.290
  T2DM[^\*^](#table-4fn3){ref-type="fn"} insulin[^\*^](#table-4fn3){ref-type="fn"} DR           1.23910    0.49206          0.010
  T1DM[^\*^](#table-4fn3){ref-type="fn"} DR                                                     0.98320    0.44443          0.030

**Notes.**

Multiple R-squared: 0.2895 (six cases with missing information for any variable in the model).

Reference group: LADA patients receiving insulin treatment.

Indicates the existence of interactions between variables.

"No education" identifies patients who did not complete compulsory education.

LADAlatent autoimmune diabetes of adultT2DMtype 2 diabetes mellitusT1DMtype 1 diabetes mellitusDRdiabetic retinopathy

Treatment satisfaction
----------------------

The proportion of subjects with a lower DTSQ final score differed among the study groups: LADA, 60.4%; T2DM, 52.5%; and T1DM, 41.9% (*p* = 0.049). However, individual paired comparisons between the groups did not yield statistically significant differences ([Table 5](#table-5){ref-type="table"}). The multivariate linear regression analysis of the DTSQ final score revealed no differences between the different combinations of groups according to diabetes type and insulin-treatment ([Table S2](#supp-4){ref-type="supplementary-material"}). Physical activity had a positive impact (*p* = 0.001) and former smoking had a negative impact on the DTSQ final score (*p* = 0.01).
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###### Results of the variables corresponding to the Diabetes Treatment Satisfaction Questionnaire (DTSQ) in the different study groups.
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  Items                  LADA (*N* = 48) *n* (%)   T2DM (*N* = 297) *n* (%)   T1DM (*N* = 124) *n* (%)   *p*-value[^\*^](#table-5fn2){ref-type="fn"}   *p*-LADA vs. T2DM   *p*-LADA vs. T1DM
  ---------------------- ------------------------- -------------------------- -------------------------- --------------------------------------------- ------------------- -------------------
  Hyperglycemia                                                                                          \<0.001                                       \<0.001             0.039
  frequency perception                                                                                                                                                     
  0--2                   6 (12.5)                  137 (46.1)                 36 (29)                                                                                      
  3--6                   42 (87.5)                 160 (53.9)                 88 (71)                                                                                      
  Hypoglycemia                                                                                           \<0.001                                       0.095               0.021
  frequency perception                                                                                                                                                     
  0--2                   32 (66.7)                 234 (78.8)                 55 (44.4)                                                                                    
  3--6                   16 (33.3)                 63 (21.2)                  69 (55.6)                                                                                    
  Final score                                                                                            0.049                                         0.389               0.091
  \[4,28)                29 (60.4)                 156 (52.5)                 52 (41.9)                                                                                    
  \[28,36)               19 (39.6)                 141 (47.5)                 72 (58.1)                                                                                    

**Notes.**

The groups are stratified by medians.

*p*-value for comparisons between groups.

LADAlatent autoimmune diabetes of adultT2DMtype 2 diabetes mellitusT1DMtype 1 diabetes mellitus

Concerning another measure of TS, the proportion of patients with a perception of increased hyperglycemia frequency was higher in the LADA group (87.5%) than in the T2DM (53.9%) and T1DM groups (71%; *p* \< 0.001 and *p* = 0.039, respectively). The multivariate linear regression analysis found an interaction between the type of diabetes and insulin treatment ([Table S3](#supp-5){ref-type="supplementary-material"}). The insulin-treated LADA patients had a higher hyperglycemia frequency perception than the T1DM (*p* = 0.04) and insulin-treated T2DM subjects (*p* = 0.05). Physical activity was associated with a lower hyperglycemia perception frequency (*p* = 0.002). Additionally, DR and higher HbA1c were associated with higher hyperglycemia frequency perception (*p* = 0.05 and *p* \< 0.001, respectively).

Finally, the proportion of patients with higher hypoglycemia frequency perception differed among the groups (*p* \< 0.001; [Table 5](#table-5){ref-type="table"}). A higher proportion of patients with T1DM (55.6%) than patients with LADA (33.3%) reported a high frequency of perceived hypoglycemia (*p* = 0.021). In the multivariate linear regression analysis ([Table S4](#supp-6){ref-type="supplementary-material"}), T2DM patients without insulin treatment showed a significantly lower hypoglycemia frequency perception compared with insulin-treated LADA subjects (*p* = 0.006). Additionally, the following conditions increased this measure: T1DM (*p* = 0.02), female sex (*p* = 0.001) and disease duration (*p* = 0.006).

Discussion
==========

In the current study, we demonstrated that LADA patients presented with lower diabetes-associated specific and average weighted impact QoL scores than patients with T2DM; however, we found no differences in terms of present QoL. Insulin treatment had a negative impact on diabetes-specific QoL, and the subgroup of insulin-treated patients with LADA did not differ from other insulin-treated groups (T2DM and T1DM) in this regard; however, the average weighted impact score was poorer in insulin-treated LADA subjects than in their corresponding T2DM counterparts. The group with the worst values for this impact score was the subgroup of LADA patients with DR and insulin treatment.

Although there was a significant difference in the DTSQ final score among the groups, paired comparisons between groups did not reach significant differences; however, there were differences concerning the hyperglycemia and hypoglycemia frequency perception among the groups. The LADA patients showed an increased hyperglycemia frequency perception compared with the T2DM and T1DM groups, which was mainly at the expense of the insulin-treated LADA group. In contrast, the LADA patients had an improved hypoglycemia perception frequency compared with the T1DM patients.

To our knowledge, there are no previous studies on QoL and TS in subjects with LADA. Concerning quality of life, previous studies revealed a lower QoL in patients with type 1 diabetes or insulin-treated type 2 diabetes and in subjects with one or more late diabetic complications ([@ref-11]). In a previous study by our group, we also found that patients with T2DM and DR had a lower QoL than those without this complication ([@ref-2]), which is in line with the current findings in patients with LADA. Our results are also in line with other previous studies that reported that insulin therapy and diabetic complications were associated with a poorer QoL in patients with T2DM ([@ref-8]; [@ref-11]; [@ref-12]; [@ref-29]; [@ref-30]; [@ref-33]); however, in a longitudinal study of patients with T2DM starting insulin therapy, QoL improved six months after the commencement of insulin therapy ([@ref-35]). The negative impact of insulin treatment on LADA patients is associated with a poorer QoL perception, which may be linked to impaired metabolic control and the delayed initiation of insulin treatment. Furthermore, [@ref-12] observed that diabetic patients with poor metabolic control had a low QoL; however, we found no significant differences in terms of glycemic control.

[@ref-29] described that the ADDQoL average weighted impact score was lower in association with male gender, higher education level and longer disease duration. Other studies have related lower QoL to advanced age, female sex, lower educational level, obesity, the presence of diabetic comorbidities, poorer glycemic control and lower socioeconomic status in the type 1 and type 2 diabetic populations ([@ref-1]; [@ref-8]; [@ref-11]; [@ref-20]; [@ref-26]; [@ref-27]; [@ref-29]; [@ref-30]; [@ref-33]). These findings are similar to our results concerning the presence of complications (i.e., DR), longer disease duration and waist circumference, all of which were related to a lower QoL.

However, we found a positive relationship between QoL and physical activity in patients with diabetes. Physical activity is an important component of the lifestyle measures used to treat patients living with diabetes. [@ref-20] performed a longitudinal study of 490 T1DM and 1,147 T2DM patients to investigate the determinants of health-related QoL (HRQoL). The authors also found a higher HRQoL in patients with a high physical activity level.

Concerning TS, the results showed a relatively high score despite the negative impact of diabetes on QoL, which has been reported in previous studies ([@ref-8]; [@ref-30]; [@ref-31]). We could not detect any difference between the LADA patients and the other groups in the DTSQ final score. Nevertheless, the hyperglycemia frequency perception was worse in the insulin-treated LADA patients, although glycemic control was not different between the groups. The increased hyperglycemia frequency perception in the subjects with LADA may be attributable to previous poorer glycemic control compared with type 1 diabetic patients under stable control. It is worth noting that the LADA subjects were recruited from a specialized hospital clinic, where patients are usually referred from primary care because of poor glycemic control. In contrast, the frequency of hypoglycemia perception was similar between the LADA and T2DM patients and was clearly increased in T1DM patients. This finding could be attributed to a higher intensity of insulin treatment in T1DM, which may be associated with a higher frequency of hypoglycemia in these patients. Unfortunately, the frequency of previous mild and severe hypoglycemia episodes was not assessed. Additionally, as expected from the exposure to insulin treatment, the insulin-treated LADA patients had an increased frequency of hypoglycemia compared with the non-insulin treated T2DM patients.

Improved TS has been associated with optimal glycemic control (HbA1c ≤ 7%) in T2DM without concomitant complications or insulin treatment ([@ref-5]; [@ref-24]). These findings are in line with those reported here. Furthermore, we found that physical activity showed a positive association with TS, as in our previous study that involved the subgroup of T2DM patients included in our study ([@ref-2]); however, we could not identify other studies addressing this specific issue in the diabetic population.

The current study has several limitations. A causal relationship between QoL, TS and related factors could not be established because of the cross-sectional study design; however, the variation in the QoL among patients was shown to be strongly influenced by the characteristics that do not vary over time ([@ref-3]). The low number of patients with LADA that were included is an important limitation. Therefore, the low number of subjects in the LADA group raises a point of caution regarding the external validity of the current results. Additionally, a significant number of potential subjects from the local LADA cohort refused to participate. However, there were no differences between the participating LADA patients and the non-participating LADA patients in the proportion of comorbidities that could affect the main study outcomes. Thus, the current study should be considered an exploratory investigation that raises awareness of the need for further studies of patient-oriented outcomes in subjects with LADA. Additionally, the current study compared the QoL and TS of LADA patients with that of patients with the two main classical types of diabetes. Another limitation arises from the potential selection bias of the current study hospital setting. Subjects with worse glycemic control are referred to specialized care for further diagnostic work-up that leads to the final diagnosis of LADA, while subjects with LADA who have better glycemic control are likely to remain unidentified at the primary care level. Therefore, the current results may not be extrapolated to the whole population of LADA subjects. The issue of poor QoL is very relevant to patients with LADA who are ultimately referred to specialized care because of unstable glycemic control and the need for insulin treatment. Finally, mental well-being may have an impact on the main outcomes evaluated in the current study. Although mood items are included in the ADDQoL-19 questionnaire, a proper evaluation of emotional or mental well-being was not performed in this study. This latter issue should be taken into consideration in future studies of patients with LADA.

Conclusions
===========

In conclusion, in the current study we found that that LADA patients with DR who were undergoing insulin treatment had a negative QoL compared with T2DM and T1DM patients. Furthermore, the LADA patients undergoing insulin treatment perceived a greater frequency of hyperglycemia than the other diabetic groups. Further research is warranted to study the status and changes over time in the QoL and TS of patients with LADA in other settings and with a larger number of patients.
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